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Background: In recent years, red yeast rice (RYR) supplements have been marketed aggressively as a natural way
to lower cholesterol; however, the large majority of commercially available products have not been studied
according to current research standards.
Methods: In a double blind placebo controlled randomized trial, 52 physicians and their spouses with a total
cholesterol level of > 200 mg/dL were randomly allocated to receive a RYR extract or placebo for 8 weeks. As a
primary outcome measure, we compared the before-after difference in lipid levels between both groups. As
secondary outcome measures we looked at side-effects, CK elevation and a change in cardiovascular risk.
Results: LDL (low density lipoprotein) cholesterol was lowered with 36 mg/dL (22%) and total cholesterol with
37 mg/dL (15%) in the intervention group. This result was statistically significant as compared to the control group,
in which no reduction in total cholesterol and LDL was observed (p < 0.001). There was no marked difference in CK
(creatine kinase)-elevation or reported side-effects between study groups. In 5/31 participants in the intervention
group, the lipid lowering effect resulted in lower cardiovascular risk as measured with SCORE (Systematic COronary
Risk Evaluation).
Conclusions: The RYR formulation under study was effective in lowering cholesterol and LDL cholesterol in this
study population. RYR therapy may be an attractive and relatively well studied alternative in patients who are
intolerant for statins or who have objections against pharmacological lipid lowering. However, consumers need to
be warned that the actual content of commercially available preparations is not assured by governmental
regulations, which raises effectiveness and safety issues.
Trial registration: Clinicaltrials.gov, nr: NCT01558050
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In recent years, red yeast rice (RYR) supplements have
encountered increasing research interest for their possible
lipid-lowering effects. Whereas the evidence in favor of
these products is still being developed and refined, dietary
supplement industries have proceeded without delay to
produce a number of RYR formulations. These food sup-
plements are marketed and mediatized as a “natural” al-
ternative to lipid lowering drugs and as a solution for
patients who experience statin-associated myalgia.* Correspondence: Veronique.verhoeven@ua.ac.be
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distribution, and reproduction in any mediumRYR, which has been used for centuries in China as a
food colorant and in traditional medicine “to invigorate
the body, aid in digestion, and revitalize the blood” [1], is
produced by culturing the yeast Monascuspurpureus on
rice. This process results in the production of a mixture of
monacolins, which are inhibitors of hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase and thus inhibit chol-
esterol synthesis in the liver. Monacolin K is chemically
identical to the statin commercialized as lovastatin.
RYR products are now widely available as over-the-
counter products; however, monacolin levels per gram
of labeled “active product” are not standardized and show
substantial variability among marketed products [2]. It is
not possible to make a comparison between formulations,
and information on labels and actual content may differ.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
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popular, physicians should be prepared to answer ques-
tions and to determine their position regarding alternative
therapies. However, as in many countries, the efficacy of
none of the RYR preparations on the Belgian market has
been studied in a satisfactory way, making any informed
advice for consumers impossible. Therefore, with the help
of physicians in the field who acted as study partici-
pants, we conducted a randomized, double-blind, placebo-
controlled trial to determine the efficacy of red yeast rice as
dietary supplement in reducing lipids.
Methods
The study was conducted from March to June 2012. Par-
ticipants were medical doctors and their partners who
were invited via an advertisement in a free medical jour-
nal in Flanders, Belgium. Eligible candidates were men
and women over age 18 with a total fasting cholesterol
level above 200 mg/dL. Exclusion criteria were present
treatment with statins, triglyceride values >400 mg/dL
which makes LDL estimation inaccurate [3], changes in
medication or food supplements which affect lipid levels
during the study (antihypertensive medication, especially
diuretics, ezetimibe, fibrates, omega-3 fatty acid food
supplements). No diet was imposed during the study.
We used a commercially available product containing
1,5% Monacoline K and a placebo which looked exactly
the same as the original product. Every capsule con-
tained 5,025 mg of Monacolin K; furthermore the prod-
uct contained Ubiquinone (Co-enzyme Q-10) 30 mg,
Procyanidins (Vitisvinifera L) 20 mg and Lecithin 100 mg.
The content of the capsules was analyzed by an inde-
pendent laboratory, certified by the Belgian Federal Public
Service for health, food chain safety and environment
(laboratory ECCA nv, Belgium, report number 11–008161).
Monacolin K was detected using an in-house liquid chro-
matography–mass spectrometry method. The formulation
was tested for the presence of heavy metals (As, Cd, Hg,
Pb), benzo-a-pyrene and mycotoxins (citrinin).
A sample size calculation based on SD (standard devi-
ation) values in previous studies, determined that 40
patients were needed to establish a mean difference in
LDL-cholesterol reduction of 15% between both groups
(power 0.80, significance level 0.05). LDL reduction was
chosen for sample size calculation because it is the most
commonly used surrogate endpoint for cardiovascular
disease reduction, and it is the primary target for statin
therapy in cholesterol-lowering guidelines [4-7].
Participants were randomized by the chief investigator
(VV) to the control or intervention group in an 1:1 ratio,
by randomly generating even (for intervention) and uneven
(for control) numbers using a computer program (www.
random.org). No stratification for age, sex or cholesterol
level was performed. If a couple of a doctor and his partnerparticipated, a random number was produced for the doc-
tor, and his/her partner was automatically allocated to the
other group. The product and placebo were administered
in a neutral, white container and labeled with a colored
tag. Study participants were instructed to take 2 capsules
every evening for 8 weeks.
Study groups were blinded to participants as well as
researchers. After completion of the analyses, the key for
control and intervention group (the color of the tag for
placebo and for active product) was obtained from the
manufacturer.
Blood samples were taken twice during the study period:
a baseline measurement before starting with the dietary
supplement and a second measurement after eight weeks.
Fasting plasma cholesterol, HDL (high density lipopro-
tein), LDL and triglycerides were measured; the second
measurement included CK levels.
At the end of the study, participants filled in a struc-
tured questionnaire regarding cardiovascular risk status
and eventual side-effects. They were specifically asked for
the following possible side-effects: muscle ache, muscle
weakness, muscle stiffness, muscle cramps, arthralgia,
sleeping disorders, depression, hair loss, and erectile
dysfunction [8,9]. Furthermore, participants could report
other possible side-effects.
As a primary outcome measure we compared the before-
after intervention difference in lipid levels, especially
LDL cholesterol, between the intervention and the con-
trol group, using the independent samples t-test. As
secondary outcome measures we looked at side-effects,
CK elevation and a change in cardiovascular risk.Statistical
analyses were performed using SPSS, SPSS Inc, Chicago,
Illinois, USA.
The study protocol got ethical approval by the university
board of Antwerp University (number 01558050), and it
was registered at clinicaltrials.gov, nr NCT01558050.
Participants provided written consent for participation
in the study.Results
Fifty-six participants were recruited for the study. Two study
candidates were excluded because of triglyceride values >
400. Fifty-four participants were randomized by generating
even and uneven numbers; the fact that more participants
were allocated to the intervention group (31versus 23) was
not deliberate. Two eligible candidates agreed to participate
in the study and provided a first blood sample, but they
failed to start to take the study product. They were ex-
cluded from analysis; thus a per protocol analysis was
performed on 52 participants. Their baseline character-
istics are shown in Table 1.
The flow of participants through the study is shown
in Figure 1.
Table 1 Baseline characteristics of study participants
Intervention group (n = 31) Placebo group (n = 21) p-value*
Age (mean, SD) 55 (7) 55 (11) 0,97
%Male /%Female 61/39 43/58 0,26
Mean total cholesterol in mg/dl (SD) 244 (28) 233 (26) 0,16
Mean HDL in mg/dL (SD) 66 (17) 60 (16) 0,21
Mean LDL in mg/dL (SD) 154 (29) 148 (22) 0,42
Mean TG in mg/dL (SD) 119 (53) 120 (62) 0,93
Mean systolic blood pressure (SD) 118 (8,5) 123 (10,8) 0,10
Mean diastolic blood pressure (SD) 74 (8,1) 77 (6,7) 0,14
Smokers 0 1 0,40
Former smokers 12 5 0,37
Diabetes/impaired glucose tolerance 1 2 0,56
Family history of cardiovascular risk** 2 2 1,00
Cardiovascular risk profile***, median risk (range) 2 (0–5) 2 (0–4) 0,21
*Paired t-test, chi2 test, Fischer’s exact test or Mann–Whitney U test.
**Defined as having a father or brother with an ischemic event (cardiac, cerebral, or peripheral) before the age of 55 and/or a mother or sister with an ischemic
event before the age of 65.
***Ten-year risk of fatal CVD based on Belgian SCORE table (by gender, age, systolic blood pressure, total cholesterol and smoking status [6].
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in serum lipid levels before and after the intervention in
both groups. Before- and after lipid profiles are shown in
Figure 2.
The difference in LDL was normally distributed
(Kolmogorov Smirnov test = 0,53) but there was some
visible skewness to the left. Practically this means that
20% of participants in the intervention group (6/31)
experienced an effect on LDL of 0%-10%. The magnitude
of the effect in the intervention group ranged from −8.03%
to 40.46%, with a mean difference of 22.17% and a median
difference of 25,47%.
Within de intervention group, the lipid lowering effect
was not influenced by age or gender. There was a ten-
dency towards a lower effect in participants with lower
self-reported compliance (16,5% LDL reduction versus
23,8%, p = 0,17). Low compliance was defined as non-
intake of the supplement for > =10% of the time.
The cardiovascular risk according to SCORE changed
after the intervention in 5/31 subjects in the interven-
tion group; in 3 participants the 10-year risk of fatal car-
diovascular risk changed from 2 to 1%, in 2 participants
from 4 to 3%. In the control group, the risk changed
from 3 to 4% in 1/21 participant.
Mild CK elevation (less than twice the upper margin
of the normal CK reference level) was observed in 3/21
control subjects and in 5/31 participants in the interven-
tion group. In one patient in the intervention group these
CK-elevation was accompanied by muscle ache.
Self-reported possible side-effects were as follows: muscle
ache 6 times (4 in intervention group and 2 in control
group), muscle weakness 1 (0/1), muscle stiffness 2 (2/0),
muscle cramps 4 (3/1), insomnia 2 (1/1), erectile dysfunction1 (0/1), belches 1 (1/0), pruritus 1 (0/1), liver pains 1 (0/1).
No participants discontinued the intake of the study prod-
uct; however one person in the intervention group stated
that, although he did not discontinue the product for the
study, the side-effects (muscle ache) were unacceptable
to him.
Discussion
This study demonstrated that consumption of the red
rice extract under study resulted in a statistically signifi-
cant lowering of cholesterol levels. The LDL concentra-
tion, the primary target, was reduced with 22% in the
intervention group. A marked variability in the magni-
tude of the response was observed. This is similar to the
inter-individual variation in response to statins, resulting
in “poor” and “good” responders, in which genetic fac-
tors, which influence statin metabolism, seem to play an
important role [10].
The sample size of this study was sufficient to assess
effectiveness of the product under study, but does not
allow to adequately assess side-effects. Although the dif-
ference was not statistically significant, there appeared
to be slightly more muscle complaints in the interven-
tion group. Another limitation of this trial is the short
follow up time, and the fact that no baseline CK-level
was determined.
The formulation under study contained 5,025 mg of
Monacolin K per capsule, resulting in a daily dose of
10,05 mg, which is a higher dose than most commer-
cially available products. Other monacolins, which are the
result of the fermentation process, were not quantified in this
study. However, they also inhibit hydroxymethylglutaryl-
coenzyme A (HMG-CoA) reductase and thus can contribute
Assessed for eligibility (n= 56 )
Excluded  (n=2 )
Not meeting inclusion criteria (n=2 )
Declined to participate (n=0 )
Other reasons (n=0 )
Analysed  (n=31 )
Excluded from analysis (give reasons) (n=0)
Lost to follow-up (give reasons) (n=0 )
Discontinued intervention (give reasons) (n=0
)
Allocated to intervention (n=31 )
Received allocated intervention (n=31 )
Did not receive allocated intervention (give 
reasons) (n=0 )
Lost to follow-up (give reasons) (n=0 )
Discontinued intervention (give reasons) (n=0
)
Allocated to intervention (n=23 )
Received allocated intervention (n=21 )
Did not receive allocated intervention (did not 
start to take the study product) (n= 2 )
Analysed  (n=21 )
Excluded from analysis (delivered a blood 
sample but did not start to take the study 






Figure 1 Consort 2010 flow diagram.
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would be useful to do a more thorough characterization
of the different fermentation products, in order to be able
to determine the effect of each of them. Furthermore, the
possibility of spiking cannot be excluded for this product.
In the absence of valid estimations of a “natural” ratio of
Monacolin K / other monacolins, it is presently impossible
to determine whether all Monacolin K is of natural origin
in this formulation. Next to monacolins, the study product
contains other “active” substances: lecithin and procyanidins
are, without proof of a clinical effect, believed to influence
cholesterol metabolism. Furthermore the manufacturerTable 2 Mean absolute and relative difference in serum lipid
Mean difference in serum lipid level (mg/dL) Intervention group
Diff TOTchol 37,06 mg/dL
(%) (14,62)
Diff HDL −1,90 mg/dL
(%) (−2,99)
Diff LDL 35,87 mg/dL
(%) (22,17)
Diff TG 19,13 mg/dL
(%) (13,79)added coenzyme Q10 (ubiquinone) aiming to reduce the
risk of side-effects. Coenzyme Q10 deficiency has been
proposed to play a role in 3-hydroxy-3-methyl-glutaryl co-
enzyme A reductase inhibitor (statin)-induced myopathies;
evidence on the clinical benefit of coenzyme Q10 supple-
mentation in (presumed) statin-induced muscle complaints
is equivocal [11,12] and a possible effect may depend on
genetic factors [13]. The perceived effect in this study is the
result of the formulation as a whole, but it is unknown
whether the combination of the different substances in the
study product has had an additive, synergistic or even an-
tagonistic effect on cholesterol levels.levels (levels at beginning minus levels at the end)
Placebo group 95% CI of difference (%) p-value
−1,86 −52,01;-25,83 <0,001
(−1,16) (−20,89; -10,68)
0,43 (0,27) −2,20;6,87 0,31
(−3,46; 9,99)
−2,04 (−1,65) −49,77;-26,05 <0,001
(−30,46; -17,17)


















Figure 2 Absolute before and after levels of serum lipids in
study participants.
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and safety of RYR in lowering of plasma lipids. There is
also some evidence regarding effectiveness in secondary
prevention from a large multicenter, randomized, double
blind placebo-controlled study in 4870 Chinese patients
with a history of myocardial infection and moderately
hypercholesterolemia. This study showed, over a period
of 4,5 years, a reduction by one third in cardiovascular
deaths and in the need for coronary revascularization. In
high risk subgroups (diabetes, hypertension) a reduction
in coronary events was shown [14,15].
Whether RYR preparations should be considered as
dietary supplements or as drugs is still under debate. In
the US, the Food and Drug Administration (FDA) con-
siders these supplements as (unapproved) drugs when
they contain a specific, standardized amount of lova-
statin [2]. In Europe this restriction has not yet been
imposed. In addition to monacolins, most commercially
available products contain other active substances such
as Coenzym Q10, isoflavones, probiotics and others, and
manufacturers commonly do not disclose levels of active
substances in their preparations. In some products, poten-
tially harmful levels of suspected nephrotoxins have been
found [2]. Evidently, the lack of dietary supplement regu-
lations raises possible safety concerns.
Which are possible indications for RYR therapy in
clinical practice? Firstly, RYR may be an alternative for
patients with a history of statin-related adverse effects
[16]. Myopathy occurs in approximately 10% of statin-
treated patients, which a spectrum ranging from rhabdo-
myolysis to (in a vast majority) myalgias without elevation
in serum creatine kinase (CK) levels. Although a link
with statin use can often not be established with certainty,
true as well as perceived statin intolerance can under-
mine compliance [9,17]. In patients intolerant to synthetic
statins, RYR has shown to be an alternative which is mod-
erately efficient, acceptable and supported well [18,19].
However, it is no surprise that myopathy, including
rhabdomyolysis, has also been reported in patients takingproducts containing RYR [20,21]. It should be kept in
mind that RYR, as any other HMG-CoA reductase inhibi-
tor, can cause myopathy, although up to now it does not
seem to be a common finding.
A second group of potential users are people who re-
fuse to take statins for philosophical reasons [22]. The
growing group of patients who have an aversion to
chronic drug intake will certainly lead to more questions
in the doctor’s office for alternative therapies [23]. Func-
tional foods like RYR can be an attractive and relatively
well studied option for these patients. Evidently they
need to be informed that also naturally occurring statins
contain pharmacologically active molecules which repre-
sent a (low) possibility of side-effects [23].
A third, more speculative use of RYR may in be people
with elevated cholesterol/ LDL levels, but who still have
a low cardiovascular risk when other risk factors are
taken into account. There is compelling evidence for
statin therapy for secondary prevention but for primary
prevention, cost-effectiveness and effect on quality of life
are less clear [24-26]. Primary prevention, even in low
risk individuals, has both strong proponents and strong
opponents. Whereas conclusive evidence is lacking, annual
spending on statins represents an enormous expenditure
for the health care budget [27]. In ten years’ time, the
amount of statin DDDs (defined daily doses) delivered
was multiplied by 20 in Belgium, representing a cost of
225607858 euros, which is 7% of the overall expenditure
for ambulatory drugs in Belgium [28]; atorvastatin and
rosuvastatin rank respectively first and third in the list of
net drug expenses in the ambulatory sector [29]. At the
same time, although not (yet) supported by direct evidence
from trials [30,31] target values for LDL cholesterol keep
being set lower [32]. In the absence of definitive evidence
and to relieve the health care budget, people at low risk
who still wish to lower their lipid levels may use functional
foods like RYR at their own expense. However, an alterna-
tive would be to use a statin at peoples’ own expense
- evidently the government has an crucial responsibility in
determining the conditions for reimbursement of statins.
Conclusion
In this study, a commercially available RYR product
showed to be efficient in lowering cholesterol values,
with a mean LDL difference of 22%. Possible indications
for RYR therapy are intolerance of statins or refusal to
take synthetic drugs in people in whom lipid lowering
therapy is indicated. It has to be kept in mind that also
naturally occurring statins in RYR represent a risk of
muscular and other side-effects, although the risk ap-
pears to be low. Furthermore, the lack of regulation in
the food supplement industry raises issues concerning
efficiency and safety. Studies with longer follow up are
warranted to asses long-term safety and effectiveness.
Verhoeven et al. BMC Complementary and Alternative Medicine 2013, 13:178 Page 6 of 7
http://www.biomedcentral.com/1472-6882/13/178Red rice in general should not be promoted as “a nat-
ural way to lower your cholesterol [33]”, but physicians
should advice their patients on specific products that
contain proper formulations and that have been studied
according to current research standards. If these precau-
tions are taken into account, these products can be an
attractive alternative to traditional statins.
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